2026 Q2 - tulosraportti
64 päivää sitten
‧32 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 | - | - | ||
| 2 | - | - | ||
| 6 955 | - | - | ||
| 1 750 | - | - | ||
| 811 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·2 t sittenBioporto is making hay while the sun shines, I have lost count of how many trade fairs and conferences they have attended this year. I can see on their website that they are going to 3 more trade fairs this year. https://bioporto.com/events/
·2 t sittenIt is very strange that 2 trades at 16.59 of respectively 2 and 7 pcs help to get the price from 1.025 to 0.994 - what is happening here ?
The short answer is that you have invested in an illiquid stock where even the slightest brain fart from 3D can move the share price significantly.
·2 päivää sittenIt is very interesting that professor, Dr. Med, Jun Oh’s independent presentation on October 7, 2026 at BioPorto in Copenhagen is now available. He presented NGAL as a necessary paradigm shift in everyday clinical practice: Until now, the global KDIGO guidelines (which have not been updated since 2012) have effectively overlooked biomarkers. Without an official KDIGO recommendation, the NGAL test has merely been seen as a "nice-to-have" supplementary research tool rather than a clinical requirement. That is only changing now with the new guidelines in late 2026. * Catalyst for adoption: When an independent KOL of his caliber adopts a product and speaks warmly of it, it creates a "snowball effect". Other hospitals and physicians worldwide trust a respected professor colleague far more than a sales signal from BioPorto itself, which accelerates adoption. * Strengthening the commercial case: His open interest and data support, as well as thorough assessment of the need where his slides show the need for NGAL (the size of the potential market for NGAL), validate the market potential toward major distribution partners (such as Roche and Beckman Coulter). It removes commercial skepticism and shows investors that BioPorto's test is not just "a smart idea", but a real tool that is already being integrated at top European hospitals. He assesses the need for the NGAL test as critical and acute. He has emphasized this by stating that he now uses the NGAL test routinely in his own department to catch kidney injuries in time and save patients from dialysis. Dr. Jun Oh is precisely the type of top clinician whose professional stamping of approval pharmaceutical and diagnostics companies dream of having behind them: * International heavyweight: He is a highly respected name at international medical conferences and is a Council Member in the two leading professional societies: European Society for Paediatric Nephrology (ESPN) and Gesellschaft für Pädiatrische Nephrologie (GPN). * Expert in European networks: Dr. Jun Oh has been appointed as official clinical expert and coordinator in the European Reference Network for Rare Kidney Diseases (ERKNet). This network sets the standard for the treatment of rare kidney diseases throughout Europe. * Focus on guidelines: Due to his broad engagement in randomized clinical trials and patient registries, he is one of the key figures whose professional assessments carry heavy weight when new clinical guidelines (including KDIGO) are formulated and presented at conferences. His absolute specialty is paediatric nephrology (kidney diseases in children) and organ transplantations. He leads one of Europe's largest transplantation programs for infants and children. He has published over 100 original scientific articles (“peer reviewed publications”). *The presentation: https://www.inderes.dk/en/videos/bioporto-from-reaction-to-prevention-in-aki?utm_source=nordnet&utm_medium=integrationPreston, you write among other things: "It removes commercial skepticism and shows investors that BioPorto's test is not just "a smart idea", but a real tool that is already being integrated into top European hospitals". When I look at the stock, I see no sign that investors' skepticism has been removed. The stock market has always been known for being many months ahead of almost any event, and yet, even though in this chat again and again and for a long time now it has been stated that it is almost a mere formality for KDIGO to change their recommendations in favor of ngal and BioPorto, I see no sign of increased volume and buying interest, and the stock price, well, it certainly hasn't been rising, rather the opposite. Where do you yourself concretely see actual signs that investors' skepticism has been removed?- ·2 päivää sittenHow wonderful to hear all your negative information that affects the share price. Hope you have sold your shares.The people who speak negatively about this stock and do not have evidence to back up their views probably do not own the stock. I believe that people are smarter than to let themselves be influenced by bitter people who have lost money on the stock, but check for themselves whether there might be something to the talk. People can just take a copy and run it through AI, and ask AI to read it thoroughly and the answer must be true, which I think they also do.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 153 088 | 153 088 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 153 088 | 153 088 | 0 | 0 |
2026 Q2 - tulosraportti
64 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenBioporto is making hay while the sun shines, I have lost count of how many trade fairs and conferences they have attended this year. I can see on their website that they are going to 3 more trade fairs this year. https://bioporto.com/events/
- ·2 t sittenIt is very strange that 2 trades at 16.59 of respectively 2 and 7 pcs help to get the price from 1.025 to 0.994 - what is happening here ?The short answer is that you have invested in an illiquid stock where even the slightest brain fart from 3D can move the share price significantly.
- ·2 päivää sittenIt is very interesting that professor, Dr. Med, Jun Oh’s independent presentation on October 7, 2026 at BioPorto in Copenhagen is now available. He presented NGAL as a necessary paradigm shift in everyday clinical practice: Until now, the global KDIGO guidelines (which have not been updated since 2012) have effectively overlooked biomarkers. Without an official KDIGO recommendation, the NGAL test has merely been seen as a "nice-to-have" supplementary research tool rather than a clinical requirement. That is only changing now with the new guidelines in late 2026. * Catalyst for adoption: When an independent KOL of his caliber adopts a product and speaks warmly of it, it creates a "snowball effect". Other hospitals and physicians worldwide trust a respected professor colleague far more than a sales signal from BioPorto itself, which accelerates adoption. * Strengthening the commercial case: His open interest and data support, as well as thorough assessment of the need where his slides show the need for NGAL (the size of the potential market for NGAL), validate the market potential toward major distribution partners (such as Roche and Beckman Coulter). It removes commercial skepticism and shows investors that BioPorto's test is not just "a smart idea", but a real tool that is already being integrated at top European hospitals. He assesses the need for the NGAL test as critical and acute. He has emphasized this by stating that he now uses the NGAL test routinely in his own department to catch kidney injuries in time and save patients from dialysis. Dr. Jun Oh is precisely the type of top clinician whose professional stamping of approval pharmaceutical and diagnostics companies dream of having behind them: * International heavyweight: He is a highly respected name at international medical conferences and is a Council Member in the two leading professional societies: European Society for Paediatric Nephrology (ESPN) and Gesellschaft für Pädiatrische Nephrologie (GPN). * Expert in European networks: Dr. Jun Oh has been appointed as official clinical expert and coordinator in the European Reference Network for Rare Kidney Diseases (ERKNet). This network sets the standard for the treatment of rare kidney diseases throughout Europe. * Focus on guidelines: Due to his broad engagement in randomized clinical trials and patient registries, he is one of the key figures whose professional assessments carry heavy weight when new clinical guidelines (including KDIGO) are formulated and presented at conferences. His absolute specialty is paediatric nephrology (kidney diseases in children) and organ transplantations. He leads one of Europe's largest transplantation programs for infants and children. He has published over 100 original scientific articles (“peer reviewed publications”). *The presentation: https://www.inderes.dk/en/videos/bioporto-from-reaction-to-prevention-in-aki?utm_source=nordnet&utm_medium=integrationPreston, you write among other things: "It removes commercial skepticism and shows investors that BioPorto's test is not just "a smart idea", but a real tool that is already being integrated into top European hospitals". When I look at the stock, I see no sign that investors' skepticism has been removed. The stock market has always been known for being many months ahead of almost any event, and yet, even though in this chat again and again and for a long time now it has been stated that it is almost a mere formality for KDIGO to change their recommendations in favor of ngal and BioPorto, I see no sign of increased volume and buying interest, and the stock price, well, it certainly hasn't been rising, rather the opposite. Where do you yourself concretely see actual signs that investors' skepticism has been removed?
- ·2 päivää sittenHow wonderful to hear all your negative information that affects the share price. Hope you have sold your shares.The people who speak negatively about this stock and do not have evidence to back up their views probably do not own the stock. I believe that people are smarter than to let themselves be influenced by bitter people who have lost money on the stock, but check for themselves whether there might be something to the talk. People can just take a copy and run it through AI, and ask AI to read it thoroughly and the answer must be true, which I think they also do.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 | - | - | ||
| 2 | - | - | ||
| 6 955 | - | - | ||
| 1 750 | - | - | ||
| 811 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 153 088 | 153 088 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 153 088 | 153 088 | 0 | 0 |
2026 Q2 - tulosraportti
64 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenBioporto is making hay while the sun shines, I have lost count of how many trade fairs and conferences they have attended this year. I can see on their website that they are going to 3 more trade fairs this year. https://bioporto.com/events/
- ·2 t sittenIt is very strange that 2 trades at 16.59 of respectively 2 and 7 pcs help to get the price from 1.025 to 0.994 - what is happening here ?The short answer is that you have invested in an illiquid stock where even the slightest brain fart from 3D can move the share price significantly.
- ·2 päivää sittenIt is very interesting that professor, Dr. Med, Jun Oh’s independent presentation on October 7, 2026 at BioPorto in Copenhagen is now available. He presented NGAL as a necessary paradigm shift in everyday clinical practice: Until now, the global KDIGO guidelines (which have not been updated since 2012) have effectively overlooked biomarkers. Without an official KDIGO recommendation, the NGAL test has merely been seen as a "nice-to-have" supplementary research tool rather than a clinical requirement. That is only changing now with the new guidelines in late 2026. * Catalyst for adoption: When an independent KOL of his caliber adopts a product and speaks warmly of it, it creates a "snowball effect". Other hospitals and physicians worldwide trust a respected professor colleague far more than a sales signal from BioPorto itself, which accelerates adoption. * Strengthening the commercial case: His open interest and data support, as well as thorough assessment of the need where his slides show the need for NGAL (the size of the potential market for NGAL), validate the market potential toward major distribution partners (such as Roche and Beckman Coulter). It removes commercial skepticism and shows investors that BioPorto's test is not just "a smart idea", but a real tool that is already being integrated at top European hospitals. He assesses the need for the NGAL test as critical and acute. He has emphasized this by stating that he now uses the NGAL test routinely in his own department to catch kidney injuries in time and save patients from dialysis. Dr. Jun Oh is precisely the type of top clinician whose professional stamping of approval pharmaceutical and diagnostics companies dream of having behind them: * International heavyweight: He is a highly respected name at international medical conferences and is a Council Member in the two leading professional societies: European Society for Paediatric Nephrology (ESPN) and Gesellschaft für Pädiatrische Nephrologie (GPN). * Expert in European networks: Dr. Jun Oh has been appointed as official clinical expert and coordinator in the European Reference Network for Rare Kidney Diseases (ERKNet). This network sets the standard for the treatment of rare kidney diseases throughout Europe. * Focus on guidelines: Due to his broad engagement in randomized clinical trials and patient registries, he is one of the key figures whose professional assessments carry heavy weight when new clinical guidelines (including KDIGO) are formulated and presented at conferences. His absolute specialty is paediatric nephrology (kidney diseases in children) and organ transplantations. He leads one of Europe's largest transplantation programs for infants and children. He has published over 100 original scientific articles (“peer reviewed publications”). *The presentation: https://www.inderes.dk/en/videos/bioporto-from-reaction-to-prevention-in-aki?utm_source=nordnet&utm_medium=integrationPreston, you write among other things: "It removes commercial skepticism and shows investors that BioPorto's test is not just "a smart idea", but a real tool that is already being integrated into top European hospitals". When I look at the stock, I see no sign that investors' skepticism has been removed. The stock market has always been known for being many months ahead of almost any event, and yet, even though in this chat again and again and for a long time now it has been stated that it is almost a mere formality for KDIGO to change their recommendations in favor of ngal and BioPorto, I see no sign of increased volume and buying interest, and the stock price, well, it certainly hasn't been rising, rather the opposite. Where do you yourself concretely see actual signs that investors' skepticism has been removed?
- ·2 päivää sittenHow wonderful to hear all your negative information that affects the share price. Hope you have sold your shares.The people who speak negatively about this stock and do not have evidence to back up their views probably do not own the stock. I believe that people are smarter than to let themselves be influenced by bitter people who have lost money on the stock, but check for themselves whether there might be something to the talk. People can just take a copy and run it through AI, and ask AI to read it thoroughly and the answer must be true, which I think they also do.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 | - | - | ||
| 2 | - | - | ||
| 6 955 | - | - | ||
| 1 750 | - | - | ||
| 811 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 153 088 | 153 088 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 153 088 | 153 088 | 0 | 0 |